News & Updates
Filter by Specialty:
Amivantamab-lazertinib bests osimertinib in head-to-head trial on lung cancer
In the phase III MARIPOSA trial, the amivantamab-lazertinib cocktail outdid osimertinib as first-line (1L) treatment for EGFR-mutated, advanced non-small cell lung cancer (NSCLC).
Amivantamab-lazertinib bests osimertinib in head-to-head trial on lung cancer
08 Nov 2023
Nirmatrelvir-ritonavir benefits persist against COVID
Management of most adults with COVID-19, particularly those with mild-to-moderate disease, is increasingly occurring in the outpatient setting due to the availability of effective treatment options.
Nirmatrelvir-ritonavir benefits persist against COVID
07 Nov 2023
Face mask use tied to cardiovascular symptoms
Use of face masks remains an effective method in preventing COVID-19 transmission, but a recent study in Singapore has found that wearing of face masks is also associated with more self-reported cardiovascular symptoms.
Face mask use tied to cardiovascular symptoms
20 Oct 2023
Beta strain-containing bivalent vaccine protects against various SARS-CoV-2 variants
A Beta variant-containing vaccine conferred protection against different SARS-CoV-2 variants, with an acceptable safety profile in adults <60 years, a phase III trial has shown.
Beta strain-containing bivalent vaccine protects against various SARS-CoV-2 variants
20 Oct 2023
First-line therapies for advanced NSCLC improve survival, QoL
Clinical trials on first-line therapies for advanced or metastatic nonsmall cell lung cancer (NSCLC) from 2010 to 2020 have reported better survival and a steady improvement in quality of life (QoL) among patients, according to the results of a systematic review.